Vicarious Surgical (RBOT) EBITDA (2020 - 2025)

Vicarious Surgical (RBOT) has reported EBITDA for 6 consecutive years, with -$11.5 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, EBITDA rose 35.21% year-over-year to -$11.5 million in Q3 2025; TTM through Sep 2025 was -$55.7 million, a 16.94% increase from a year earlier, with the FY2024 full-year figure at -$66.6 million, up 17.49% from the prior year.
• EBITDA was -$11.5 million for Q3 2025 at Vicarious Surgical, up from -$13.5 million in the prior quarter.
• Over five years, EBITDA peaked at -$5.2 million in Q1 2021 and troughed at -$22.3 million in Q1 2023.
• A 5-year average of -$16.1 million and a median of -$17.7 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 24660.34% in 2021 and jumped 35.21% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$17.8 million in 2021, then retreated by 15.66% to -$20.6 million in 2022, then increased by 24.59% to -$15.5 million in 2023, then advanced by 3.62% to -$15.0 million in 2024, then advanced by 23.2% to -$11.5 million in 2025.
• The last three EBITDA figures came in at -$11.5 million (Q3 2025), -$13.5 million (Q2 2025), and -$15.7 million (Q1 2025), per Business Quant data.